STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

about

Opportunities to Apply the 3Rs in Safety Assessment Programs.Reducing blood volume requirements for clinical pathology testing in toxicologic studies-points to consider.

P2860

Q38774773-2AA08A3D-5670-4FFA-9421-5983DCD4746E Q39034164-A5D00A84-391B-4B34-BC98-10351112415C

P2860

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

Item

http://www.wikidata.org/entity/Q39995176

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@en

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@nl

type

Item

label

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@en

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@nl

prefLabel

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@en

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@nl

P1476

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

@en

P2093

Allison Vitsky

http://www.w3.org/2001/XMLSchema#string

Daniela Ennulat

http://www.w3.org/2001/XMLSchema#string

Denise I Bounous

http://www.w3.org/2001/XMLSchema#string

Florence M Poitout-Belissent

http://www.w3.org/2001/XMLSchema#string

Lila Ramaiah

http://www.w3.org/2001/XMLSchema#string

Lindsay Tomlinson

http://www.w3.org/2001/XMLSchema#string

Niraj K Tripathi

http://www.w3.org/2001/XMLSchema#string

Valerie G Barlow

http://www.w3.org/2001/XMLSchema#string

P2860

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Lies, damn lies, and reference intervals (or hysterical control values for clinical pathology data)

Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat.

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.

Assessment of myelotoxicity caused by environmental chemicals.

Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies.

Strategic approach to fit-for-purpose biomarkers in drug development.

Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.

Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.

Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.

P304

163-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0192623315624165

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26879687

http://www.w3.org/2001/XMLSchema#string

P921

best practice

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

about

P2860

P2860

STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921